GC Wealth Management RIA LLC Purchases 353 Shares of GSK plc (NYSE:GSK)

GC Wealth Management RIA LLC raised its position in GSK plc (NYSE:GSK) by 2.6% in the 4th quarter, Holdings Channel reports. The firm owned 14,009 shares of the pharmaceutical company’s stock after buying an additional 353 shares during the quarter. GC Wealth Management RIA LLC’s holdings in GSK were worth $474,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. FMR LLC raised its position in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares in the last quarter. Miller Howard Investments Inc. NY purchased a new stake in shares of GSK during the 4th quarter valued at $23,366,000. Finally, Bridgewater Associates LP raised its position in shares of GSK by 107.3% during the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after buying an additional 500,010 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GSK shares. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

GSK stock opened at $39.47 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $81.81 billion, a PE ratio of 24.82, a P/E/G ratio of 1.12 and a beta of 0.58. The firm has a fifty day simple moving average of $35.72 and a two-hundred day simple moving average of $37.10. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 3.98%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.